| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4868259
Max Phase: Preclinical
Molecular Formula: C17H17ClN6O
Molecular Weight: 356.82
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CNC(=O)c1c(Cc2ccccc2)c(-c2cc(Cl)nc(N)n2)nn1C
Standard InChI: InChI=1S/C17H17ClN6O/c1-20-16(25)15-11(8-10-6-4-3-5-7-10)14(23-24(15)2)12-9-13(18)22-17(19)21-12/h3-7,9H,8H2,1-2H3,(H,20,25)(H2,19,21,22)
Standard InChI Key: FJBYBCBDRWOCQH-UHFFFAOYSA-N
Associated Targets(Human)
Adenylate cyclase type 10 96 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 356.82 | Molecular Weight (Monoisotopic): 356.1152 | AlogP: 2.06 | #Rotatable Bonds: 4 |
| Polar Surface Area: 98.72 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 0.98 | CX LogP: 2.66 | CX LogD: 2.66 |
| Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.70 | Np Likeness Score: -1.00 |
References
| 1. Fushimi M, Buck H, Balbach M, Gorovyy A, Ferreira J, Rossetti T, Kaur N, Levin LR, Buck J, Quast J, van den Heuvel J, Steegborn C, Finkin-Groner E, Kargman S, Michino M, Foley MA, Miller M, Liverton NJ, Huggins DJ, Meinke PT.. (2021) Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10)., 12 (8.0): [PMID:34413957] [10.1021/acsmedchemlett.1c00273] |
Source
Source(1):